IDENTIFYING MULTI-MODALITY IMAGING CORRELATES OF DEMENTIA WITH LEWY BODIES AND AD

$129,647P50FY2013AGNIH

Mayo Clinic Rochester, Rochester MN

Investigators

Linked publications & trials

Paper 39677464 Paper 39535480 Paper 39465382 Paper 39444005 Paper 39439201 Paper 39379761 Paper 39371140 Paper 39356058 Paper 39282424 Paper 39270144 Paper 39267525 Paper 39254167 Paper 39253523 Paper 39253457 Paper 39251599 Paper 39231932 Paper 39215503 Paper 39207439 Paper 39173101 Paper 39152475 Paper 39030261 Paper 38995784 Paper 38987827 Paper 38980643 Paper 38958543 Paper 38958117 Paper 38949538 Paper 38909241 Paper 38903124 Paper 38883718 Paper 38779814 Paper 38735056 Paper 38728190 Paper 38721926 Paper 38712163 Paper 38712030 Paper 38687251 Paper 38659743 Paper 38651011 Paper 38650747 Paper 38641585 Paper 38615089 Paper 38585978 Paper 38578498 Paper 38570511 Paper 38559190 Paper 38558965 Paper 38472443 Paper 38466158 Paper 38464214 Paper 38460116 Paper 38442778 Paper 38441951 Paper 38425303 Paper 38423160 Paper 38418871 Paper 38329197 Paper 38313266 Paper 38285009 Paper 38254182 Paper 38244935 Paper 38236817 Paper 38234807 Paper 38234803 Paper 38216151 Paper 38194584 Paper 38187716 Paper 38181205 Paper 38159060 Paper 38131463 Paper 38091751 Paper 38045300 Paper 38014536 Paper 38014121 Paper 37963289 Paper 37932910 Paper 37886506 Paper 37804318 Paper 37794492 Paper 37790621 Paper 37745545 Paper 37742642 Paper 37707812 Paper 37693465 Paper 37661080 Paper 37592813 Paper 37580727 Paper 37580163 Paper 37578203 Paper 37547016 Paper 37546878 Paper 37528055 Paper 37491248 Paper 37474615 Paper 37429840 Paper 37385974 Paper 37369829 Paper 37353809 Paper 37322115 Paper 37279785

Abstract

As an outcome of the proposed investigations, we expect to identify multi-modality imaging markers that together with the clinical evaluation would be useful in determining the contribution of AD and LBD pathologies to the dementia syndrome. The proposal is relevant because, with the development of disease- modifying treatments, surrogate markers for AD and LBD pathologies will be required both for treatment decisions and for monitoring treatment response.

View original record on NIH RePORTER →